Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European journal of pharmaceutics and biopharmaceutics

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejpb.2012.04.010PMID 22554766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.

  2011cited by this paper
• Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies.

  2011influential reference
• Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and In Vitro Assessment

  2011cited by this paper
• Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect.

  2010cited by this paper
• Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery.

  2010cited by this paper
• Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.

  2010cited by this paper
• Combination therapy of metronomic S‐1 dosing with oxaliplatin‐containing polyethylene glycol‐coated liposome improves antitumor activity in a murine colorectal tumor model

  2010cited by this paper
• Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.

  2009cited by this paper
• Recent advances in tumor vasculature targeting using liposomal drug delivery systems

  2009cited by this paper
• Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.

  2009cited by this paper
• Ligand-based targeted therapy for cancer tissue

  2009cited by this paper
• Tumour-targeted nanomedicines: principles and practice

  2008cited by this paper
• Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.

  2008cited by this paper
• Nanocarriers as an emerging platform for cancer therapy.

  2007cited by this paper
• Tumor Priming Enhances Delivery and Efficacy of Nanomedicines

  2007cited by this paper
• Targeted pharmaceutical nanocarriers for cancer therapy and imaging

  2007influential reference
• Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system

  2007cited by this paper
• Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling

  2007cited by this paper
• In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).

  2007cited by this paper
• Nanocarriers as an emerging platform for cancer therapy

  2007cited by this paper
• Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications

  2006cited by this paper
• Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers.

  2006cited by this paper
• Exploiting the enhanced permeability and retention effect for tumor targeting.

  2006cited by this paper
• Liposomal encapsulated anti-cancer drugs.

  2005cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• Influence of Physicochemical Properties on Pharmacokinetics of Non-viral Vectors for Gene Delivery

  2002cited by this paper
• Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide

  2002cited by this paper
• Enhanced Vascular Permeability in Solid Tumor Involving Peroxynitrite and Matrix Metalloproteinases

  2001cited by this paper
• Delivery of molecular and cellular medicine to solid tumors.

  2001cited by this paper
• Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.

  2001cited by this paper
• Macromolecule uptake in human melanoma xenografts. relationships to blood supply, vascular density, microvessel permeability and extracellular volume fraction.

  2000cited by this paper
• Low‐dose tumor necrosis factor‐α augments antitumor activity of stealth liposomal doxorubicin (DOXIL®) in soft tissue sarcoma‐bearing rats

  2000cited by this paper
• Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.

  2000cited by this paper
• Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.

  1999influential reference
• Understanding barriers to drug delivery: high resolution in vivo imaging is key.

  1999cited by this paper
• Clinical applications of TNF-α in cancer

  1998cited by this paper
• Polymer-coated long-circulating microparticulate pharmaceuticals.

  1998cited by this paper
• Clinical applications of TNF-alpha in cancer.

  1998cited by this paper
• Delivery of molecular and cellular medicine to solid tumors.

  1997cited by this paper
• Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factoryvascular permeability factor antibody (angiogenesisyvascular obstruction)

  1996influential reference
• Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide.

  1996cited by this paper
• Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin

  1996cited by this paper
• Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

  1996cited by this paper
• Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor

  1994cited by this paper
• Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II)

  1992cited by this paper
• Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

  1990cited by this paper
• Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue

  1988cited by this paper
• Transport of molecules in the tumor interstitium: a review.

  1987cited by this paper
• Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model.

  1986cited by this paper
• A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

  1986cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983influential reference
• Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues.

  1983cited by this paper
• Colorimetric assay methods for free and phosphorylated glyceric acids.

  1959cited by this paper

• EGF-induced P-gp expression in tumor vasculature contributes to therapeutic resistance to Doxorubicin-PEG-liposomes in mice bearing Doxorubicin-resistant B16-BL6 tumors

  2025cites this paper
• Nanocarrier System for Increasing the Therapeutic Efficacy of Oxaliplatin.

  2022cites this paper
• The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.

  2022cites this paper
• Effect of doxorubicin release rate from polyethylene glycol-modified liposome on anti-tumor activity in B16-BL6 tumor-bearing mice.

  2021cites this paper
• Noninvasive Molecular Imaging of the Enhanced Permeability and Retention Effect by 64Cu-Liposomes: In vivo Correlations with 68Ga-RGD, Fluid Pressure, Diffusivity and 18F-FDG

  2020cites this paper
• Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.

  2018cites this paper
• Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.

  2017cites this paper
• Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.

  2016cites this paper
• Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.

  2016cites this paper
• On the use of liposomal delivery systems for oxaliplatin and in dual drug delivery in combination with chemo-sensitizing and chemotherapeutic agents

  2016cites this paper
• Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose.

  2015cites this paper
• Improvement of anti-tumor abilities on human non-small cell lung carcinoma by micellization and cross-linking of N-(2-hydroxypropyl) methacrylamide copolymers

  2015cites this paper
• A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity.

  2015cites this paper
• Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review)

  2014cites this paper
• Fishing for fire: strategies for biological targeting and criteria for material design in anti-inflammatory therapies†

  2014cites this paper
• Prospective clinical applications of nanosized drugs

  2013cites this paper
• [A review on the influences of size and surface charge of liposome on its targeted drug delivery in vivo].

  2013cites this paper
• Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

  2013cites this paper
• Multiscale Modeling of Tumor Angiogenesis and Resistance Evolution: A Hybrid PDE–ABM Framework for Cancer Prediction and Therapy Planning

  year unknowncites this paper